Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer
Status:
Completed
Trial end date:
2018-06-28
Target enrollment:
Participant gender:
Summary
This study is investigating the effects of an experimental drug (neratinib) in combination
with paclitaxel versus trastuzumab in combination with paclitaxel for the treatment of women
who have not received previous treatment for erbB-2-positive locally recurrent or metastatic
breast cancer. The study will compare the effectiveness of each regimen in shrinking tumors
and extending the lives of women with erbB-2 (HER2) positive breast cancer. The study will
also compare the safety of the two regimens and as well as the quality of life of subjects
receiving either regimen.